NCT07517640 2026-04-08
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
Clinical Trials
19 trialsNCT07470840 2026-03-24
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT07414992 2026-02-17
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Not yet recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT07381309 2026-02-02
VVSHIP
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07379398 2026-01-30
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07309952 2025-12-30
SACTION 2501
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07258147 2025-12-02
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Phase 2 Not yet recruiting
NCT07173387 2025-09-15
RAD-NALIRIFOX
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT07152067 2025-09-03
TOPPGUN-RS
Centre Hospitalier Universitaire de Liege
Phase 2 Not yet recruiting
NCT07030140 2025-06-22
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT07007728 2025-06-06
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06991491 2025-05-28
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
West China Hospital
Phase 2 Not yet recruiting
NCT06592612 2024-09-19
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06573398 2024-08-27
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06422156 2024-05-20
Nim-PC-28
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT06391008 2024-04-30
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT06009029 2023-08-24
SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT05747716 2023-02-28
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting